Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
Median Technologies (Paris:ALMDT):
About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 minutes ago
- Business Wire
Eton Solutions Secures $58M Series C to Bring AI-Driven Wealth Management
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Eton Solutions, the wealth management platform that the world's wealthiest single and multi-family offices rely on to manage over $1 trillion in assets, today announced the finalization of its $58 Million Series C round, which unfolded in two tranches. The raise was led by repeat investor Navis Capital Partners, a leading private equity firm focused on companies in high-growth markets with an edge in their industries. The funding comes as Eton Solutions experiences rapid growth. In the past three years, the company has more than quadrupled its revenue and expanded its client base by 340% across 15 countries. The company's AtlasFive® platform has become the system of record for elite wealth management and is already in use by more than 800 of the world's wealthiest families. The company has made significant investments in artificial intelligence and expanded features to arrive at a holistic solution that's now responsible for managing 130,000 entities, overseeing 205,000+ investments, $65 billion in annual bill payments, and processing more than 14 million annual transactions. It's upon this data-rich foundation that Eton Solutions has developed more than 400 AI use cases. The company will use the funding to fuel product innovation and AI development of its AtlasFive® platform and expand its suite of products targeting the PE and Funds industry. Built on Eton Solutions' decades of wealth management and financial domain expertise, its forthcoming products will serve a broader range of ultra-high net-worth levels, beginning with individuals with $25 million or more in assets. They will also serve a steadily expanding client base for the company, now consisting of Single and Multi-Family Offices, Private Equity firms, Funds, Registered Investment Advisors, Accounting firms, Business Managers and Global Private Banks. The growth of family offices in the U.S., UK, Switzerland, APAC and the UAE. In recent years, the growth of ultra-high-net-worth families and individuals has resulted in a significant expansion of family offices globally. According to Deloitte, the number of single-family offices worldwide hit 9,030 last year and will reach 10,720 by 2030. While North America currently has the largest number of family offices, Asia Pacific is expected to outpace it in terms of growth speed by 2030. Eton Solutions, with a U.S. headquarters in North Carolina and international headquarters in Singapore, has a substantial presence in North America, Asia Pacific, Europe and the Middle East. It is well positioned–both physically and strategically–to cater to this growth and the resulting demand. 'Our total addressable market is increasing every year, and our technology is expanding to meet it,' said Satyen Patel, Executive Chairman at Eton Solutions. 'We've built an ecosystem that is uniquely able to meet every wealth management need–and has the security, privacy, workflow and data foundation necessary to do so–all in one place. Our focus as we enter our second decade is reimagining how wealth managers across the board manage liquid and alternative investments for their clients–whether one or many. This investment will let us super charge our expansion to meet the growing markets and their demand for AI-driven efficiencies that create even more value.' Over the last ten years, the company has invested $50 million in the development of its core and upcoming product releases. This year, it hosted its first ever global client summit, attracting 75 representatives from more than 40 family offices from around the world. The company has 425 employees. Navis Capital Partners, which manages over $5 billion in assets, cited Eton's unique position in the market as key to their investment decision. 'We've witnessed how Eton's technology enables family offices to achieve unprecedented efficiency and insight,' said Rajendra Pai, Partner at Navis Capital Partners. 'Their platform has become an essential infrastructure for managing complex wealth at scale. We're excited to continue supporting their growth and innovation.' Eton Solutions has built a prestigious international client base, including the founders of the world's leading technology companies, hotel groups, oil and energy companies, entertainment groups, investment firms and more. Its all-in-one technology platform seamlessly connects all data, services and stakeholders within single and multi-family offices–replacing and streamlining a workflow previously made up of several disparate point solutions and manual processes. The company's ERP platform is additionally used as a white-labeled solution by Institutional clients who manage complex liquid and alternative investments for their clients.
Business Wire
13 minutes ago
- Business Wire
Genentech Provides Update on Astegolimab in Chronic Obstructive Pulmonary Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today topline results from the pivotal Phase IIb ALIENTO (n=1,301) and the Phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The pivotal Phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualized exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given every two weeks. However, the Phase III ARNASA study did not meet its primary endpoint of a statistically significant reduction in the AER, demonstrating a numerical 14.5% reduction at 52 weeks when astegolimab was given every two weeks. The results were generally consistent across secondary endpoints in both studies. The total number of exacerbations was lower than prospectively anticipated in both trials. The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified. 'While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for managing this debilitating and complex disease,' said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'This was the first set of studies in an 'all-comers' COPD population, and we will discuss these data with regulatory authorities to evaluate next steps for astegolimab.' Detailed results from ALIENTO and ARNASA will be shared at an upcoming medical meeting. About the ALIENTO and ARNASA studies Astegolimab is an investigational, fully human anti-ST2 monoclonal antibody designed to bind with high affinity to the ST2 receptor, thereby blocking the signaling of IL-33. The astegolimab COPD pivotal program consists of two registrational studies, the Phase IIb ALIENTO (NCT05037929) and Phase III ARNASA (NCT05595642) studies. Both ALIENTO and ARNASA are double-blinded, placebo-controlled, multi-center studies that evaluate the efficacy and safety of astegolimab administered every two or every four weeks in patients with COPD on top of standard of care maintenance therapy. Patients in the studies included former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The primary analysis is based on the initial phase of the study, which consisted of 1,301 patients for ALIENTO and 1,375 patients for ARNASA. The primary endpoint is the reduction in the annualized rate of moderate and severe COPD exacerbations (AER) over the 52-week treatment period. AER is the total number of exacerbations (a sudden worsening in airway function and respiratory symptoms) occurring over the relevant treatment period, divided by the total number of patient years. Standard of care maintenance therapy for both studies was one of the following combinations - inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA); long-acting muscarinic antagonist (LAMA) plus LABA; ICS plus LAMA plus LABA. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit
CNBC
14 minutes ago
- CNBC
Brexit made businesses abandon the UK. Trump's hefty EU tariffs could bring them back
In 2016, the U.K.'s vote to leave the EU prompted many businesses to shift operations to the European continent, taking investment and headcount with them. Fast forward to 2025, and the specter of U.S. President Donald Trump's 30% trade tariffs on the EU, which will kick in on Aug.1 unless a trade deal is reached, could bring them back. "The U.K. could be a big indirect winner" if the threatened U.S. duties on the EU become a reality, according to Alex Altmann, partner and head of the German desk at London-based accountancy and business advisory firm Lubbock Fine. "If the tariff rate for the EU finally ends up anywhere near this 30% level then the U.K.'s much lower U.S. tariffs would offer a major incentive for EU companies to shift some of their manufacturing to the U.K. or to expand their existing U.K. facilities," he noted in emailed comments. "The U.K. has a lot of spare manufacturing capacity after Brexit. A big gap between U.K. and EU tariffs would be a major opportunity for the U.K. to regain some of its lost status as a key European manufacturing hub," added Altmann, who is also the vice president of the British Chamber of Commerce in Germany. As things stand, the U.K. has already struck a trade deal with the U.S. that reduces duties on cars to 10% and grants it the lowest duty on steel imports. London also has a "reset" deal with the EU, after the Labour government under Prime Minister Keir Starmer — who was opposed to Brexit — carved out a trade agreement following years of post-referendum acrimony. The sweet spot the U.K. now finds itself in comes after several years of uncertainty and angst for businesses, as they've tried to navigate a post-Brexit world of more red tape and barriers to export. That's been an ongoing gripe for exporters, given that the 27-country EU remained the U.K.'s largest trading partner after Brexit was finally enacted in 2020. The EU accounted for more than 50% of Britain's foreign trade in goods in 2024, according to the European Commission. A number of big businesses, and particularly financial services firms such as Goldman Sachs and JPMorgan, sought to avoid the transnational regulatory complexities of the post-Brexit landscape by relocating operations and assets to other financial hubs in the EU, such as Dublin, Paris, Amsterdam and Frankfurt. The exodus was ultimately not as dramatic as was initially feared. Supporters and critics argue over the merits and disadvantages of Brexit and the divorce from the EU's single market and customs union, as well as the free movement of goods and people that came with EU membership. Yet most economists agree that Brexit dented U.K. exports, jobs and economic growth. The Office for Budget Responsibility, the U.K.'s independent forecaster, estimates that exports and imports will be around 15% lower in the long run, compared to if the U.K. had remained in the EU. Although economists argue over the impact on the wider economy, it's generally agreed that the U.K.'s GDP is around 5% lower than it would have been, had Britain not voted to leave the bloc. While the U.K. is reveling in its newfound harmony with its American and European business partners, the extent of any windfall that comes as a result of the EU's trading pain with the U.S. remains to be seen. It remains unclear whether Trump's planned 30% tariff on the bloc will actually go ahead on Aug.1. The U.S. president's mercurial nature means the ultimate levy rate could go higher — he previously threatened a 50% tariff — or lower, toward the baseline 10% level that the EU is pursuing. Not everyone agrees that the U.K. could benefit from trade misfortunes that befall the EU, whatever the outcome of last-ditch talks between Brussels and Washington. "First of all, the 30% tariffs for the EU, they're not a given," Carsten Nickel, managing director at Teneo, told CNBC last week, pointing out that any potential post-tariffs shift in business investment from Europe back to the U.K. would be unlikely to happen quickly. "If we were to talk about moving production facilities from Europe to the U.K. because the U.K. has a deal with the U.S. — the time horizon for that is a multi-year, if not decade-long, kind of time horizon," he said. In addition, Nickel noted that the U.K.'s strength remained in financial services rather than in manufacturing, which remains more prevalent in export-oriented countries like Germany and Italy. "The reality is that the U.K.'s comparative advantage is not in high-end manufacturing ... so the idea that you're going with this stuff that you're currently producing in, say, Germany and Switzerland, and you're moving that to the U.K. tomorrow ... it's just not a decision that that a business leader in Europe can take just like that," Nickel said.
